Allogeneic Bone Marrow Transplantation in a Patient with Chemotherapy-Resistant Progressive Histiocytosis X

Ringdén, Olle; Åhström, L.; Lönnqvist, B; Båryd, I.; Svedmyr, Erik; Gahrton, Gösta

doi:10.1056/nejm198703193161207

Cited by 52 publications

(32 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 The OS of the 29 patients who underwent myeloablative SCT was 48% (14/29 patients), and the transplant-related mortality was 45%. However, in a recent study reported from Europe, 10 seven (78%) of nine patients survived with no signs of disease activity after RIC-SCT.…”

Section: Discussionmentioning

confidence: 94%

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan

Kudo

Ohga

Morimoto

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan

Kudo

Ohga

Morimoto

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…[9][10][11][12][13][14][15][16][17][18][19][20][21] However, myeloablative high-dose regimens are associated with a high treatment-related morbidity and mortality, especially in severely ill LCH patients. For children with other nonmalignant diseases who are not eligible for conventional myeloablative conditioning regimens, the use of reduced-intensity conditioning regimens is feasible and associated with stable engraftment and cure from the underlying disease in many cases.…”

mentioning

confidence: 99%

Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning

Steiner

Matthes‐Martin

Attarbaschi

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Children with multisystem Langerhans cell histiocytosis (LCH) and risk organ involvement who fail to respond to conventional chemotherapy have an extremely poor prognosis. Myeloablative stem cell transplantation (SCT) as a possible salvage approach for these patients has been associated with a high risk of transplant-related mortality. Therefore, allogeneic stem cell transplantation following a reduced-intensity conditioning regimen (RIC-SCT) has recently been performed as an alternative salvage approach. We report on the experience with allogeneic RIC-SCT in nine pediatric high-risk LCH patients. Conditioning regimen included fludarabine in all patients, melphalan in eight patients, total lymphoid irradiation in six patients, total body irradiation in two, antithymocyte globulin in five, and Campath in four patients. RIC-SCT was well tolerated with regard to common procedure-related complications. Two patients died 50 and 69 days after RIC-SCT, respectively. Seven out of the nine patients survived and showed no signs of disease activity (including one with nonengraftment and full autologous hematopoietic recovery) after median follow-up of 390 days post-SCT. Based on this observation, we conclude that RIC-SCT is a feasible procedure with low transplant-related morbidity and mortality and a promising new salvage approach for highrisk LCH patients with resistant risk organ involvement. Bone Marrow Transplantation (2005) 36, 215-225.

show abstract

“…Median age at diagnosis was 0.54 years. The median LCH activity score at diagnosis was 10 (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. All patients responded poorly to initial chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis of patients with disease progression after a first course of chemotherapy is very poor, [1][2][3] and hematopoietic stem cell transplantation (HSCT) may be an option in such cases. 4 HSCT has been proposed for LCH in various clinical situations, including recurrent multifocal bone lesions, adult lung involvement, and refractory LCH in children. Based on a nationwide register, we collected information on all HSCT procedures performed for refractory LCH in France over a 13-year period.…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group

Akkari

Donadieu

Piguet

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic Bone Marrow Transplantation in a Patient with Chemotherapy-Resistant Progressive Histiocytosis X

Cited by 52 publications

References 21 publications

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan

Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning

Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group

Contact Info

Product

Resources

About